Hypertension and the Cortisol-Cortisone Shuttle
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
11 beta-Hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) plays a crucial role in converting hormonally active cortisol to inactive cortisone, thereby conferring specificity on the mineralocorticoid receptor. Mutations in the gene encoding 11 beta-HSD2 (HSD11B2) account for an inherited form of hypertension, the syndrome of apparent mineralocorticoid excess, in which cortisol induces hypertension and hypokalemia. A similar clinical picture to apparent mineralocorticoid excess occurs after the ingestion of licorice and carbenoxolone, which are competitive inhibitors of 11 beta-HSD2. Reduced 11 beta-HSD2 activity may explain the increased sodium retention in preeclampsia, renal disease, and liver cirrhosis. Substrate saturation of 11 beta-HSD2 occurs in Cushing's syndrome and explains the mineralocorticoid excess state that characterizes ectopic ACTH syndrome. Polymorphic variability in the HSD11B2 gene in part determines salt sensitivity, a forerunner for adult onset hypertension. Furthermore, reduced placental 11 beta-HSD2 expression might underpin the Barker hypothesis, the epidemiological link between reduced birth weight and adult hypertension. At a prereceptor level, 11 beta-HSD2 plays a key role in normal physiology in the corticosteroid regulation of sodium homeostasis and pathophysiology of hypertension.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heterozygous carriers may have an increased risk of hypertension (598).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [598]
Citations
Cites
Barker, D. J., Osmond, C., Golding, J., Kuh, D., & Wadsworth, M. E. (1989) · BMJ · doi:10.1136/bmj.298.6673.564 · Cited by 2,415 · cited 1×
“Barker’s epidemiological studies indicate a strong correlation between low birth weight at term and cardiovascular disease risk in adulthood, and this has prompted speculation that factors involved in regulating fetal growth might in some way program the subsequent development of hypertension (and other cardiovascular…”
BackgroundArriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946 · cited 1×
“and aldosterone in vitro (4), and the inactivation of cortisol to”
BackgroundMineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628
Edwards, C. R. W., Burt, D., Mcintyre, M. A., De Kloet, E. R., Stewart, P. M., Brett, L., Sutanto, W. S., & Monder, C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90742-8 · Cited by 1,068
Self-citationStewart, P., Valentino, R., Wallace, A. M., Burt, D., Shackleton, C. L., & Edwards, C. W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91014-2 · Cited by 803 · cited 1×
“Licorice administration to normal volunteers results in a mineralocorticoid excess state, an increase in the urinary THF allo-THF/THE ratio, an increase in plasma cortisol half-life, and a decrease in circulating cortisone values, indicative of inhibition of 11 HSD2 in vivo (30, 31).”
BackgroundSelf-citation11β-Hydroxysteroid Dehydrogenase
Stewart, P. M., & Krozowski, Z. S. (1997) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)60646-9 · Cited by 718
Self-citationCloning and tissue distribution of the human 1 lβ-hydroxysteroid dehydrogenase type 2 enzyme
Albiston, A. L., Obeyesekere, V. R., Smith, R. E., & Krozowski, Z. S. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90176-7 · Cited by 712
Human hypertension caused by mutations in the kidney isozyme of 11β–hydroxysteroid dehydrogenase
Mune, T., Rogerson, F. M., Nikkilä, H., Agarwal, A. K., & White, P. C. (1995) · Nature Genetics · doi:10.1038/ng0895-394 · Cited by 619
Edwards, C. R. W., Benediktsson, R., Lindsay, R. S., & Seckl, J. R. (1993) · The Lancet · doi:10.1016/0140-6736(93)90148-a · Cited by 548 · cited 1×
“The poor growth rate seen in many children with AME is possibly due to glucocorticoid excess in utero consequent on absent or impaired 11 -HSD2 activity (66, 67).”
Background11β-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess*
White, P. C., Mune, T., & Agarwal, A. K. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0288 · Cited by 517
ULICK, S., KODAMA, T., GUNCZIER, P., ZANCONATO, G., RAMIREZ, L. C., RAUH, W., ROSLER, A., BRADLOW, H. L., & NEW, M. I. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-49-5-757 · Cited by 496
Tannin, G. M., Agarwal, A. K., Monder, C., New, M. I., & White, P. C. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)55351-5 · Cited by 436
Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
Stewart, P. M., Corrie, J. E., Shackleton, C. H., & Edwards, C. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113592 · Cited by 430 · cited 3×
“The conversion of cortisone to cortisol mediated by 11 -HSD1 is normal in AME (9, 14).”
BackgroundMethodSelf-citationLindsay, R. S., Lindsay, R. M., Edwards, C. R. W., & Seckl, J. R. (1996) · Hypertension · doi:10.1161/01.hyp.27.6.1200 · Cited by 310 · cited 1×
“Impaired placental 11 -HSD2 activity has been associated with intrauterine growth restriction and with programing of hypertension in adult life (68, 69).”
BackgroundLicorice-Induced Hypermineralocorticoidism
Farese, R. V., Biglieri, E. G., Shackleton, C. H. L., Irony, I., & Gomez-Fontes, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110243251706 · Cited by 295 · cited 1×
“Similar changes in cortisol metabolism were reported in patients presenting with licorice-induced mineralocorticoid excess (32).”
BackgroundMcTernan, C. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.10.4979 · Cited by 282 · cited 1×
“Impaired placental 11 -HSD2 activity has been associated with intrauterine growth restriction and with programing of hypertension in adult life (68, 69).”
BackgroundSelf-citationUrinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276 · cited 7×
“Both the urinary ratio of THF allo-THF/THE and UFF/UFE are elevated, not because of impaired 11 -HSD2 activity, but simply because of substrate saturation.”
BackgroundMethodInfluentialSelf-citationBrown, R. W., Chapman, K. E., Edwards, C. R., & Seckl, J. R. (1993) · Endocrinology · doi:10.1210/endo.132.6.8504762 · Cited by 271 · cited 1×
“11 -HSD2 is widely expressed in fetal tissues, including placental syncytiotrophoblasts, the barrier between maternal and fetal circulation (64, 65).”
BackgroundStewart, P. M., Gupta, A., Sheppard, M. C., Whorwood, C. B., Howie, A. J., Milford, D. V., & Krozowski, Z. S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90211-1 · Cited by 241
Self-citationConn, J. W. (1968) · JAMA · doi:10.1001/jama.205.7.492 · Cited by 218
Evidence for an Unidentified Steroid in a Child with Apparent Mineralocorticoid Hypertension
NEW, M. I., LEVINE, L. S., BIGLIERI, E. G., PAREIRA, J., & ULICK, S. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-44-5-924 · Cited by 199
Stewart, P. M. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.2.480 · Cited by 180
Self-citationStewart, P. M. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.12.3617 · Cited by 176
Self-citationDeficient inactivation of cortisol by 11β‐hydroxysteroid dehydrogenase in essential hypertension
Walker, B. R., Stewart, P. M., Shackleton, C. H. L., Padfield, P. L., & Edwards, C. R. W. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb01778.x · Cited by 174 · cited 1×
“Regarding 11 -HSD2, studies have demonstrated variations in 11 HSD activity in hypertensive subjects with increases in either the plasma [11-(3)H]cortisol half-life (48) or the THF alloTHF/THE ratio (49), but mineralocorticoid excess in patients with impaired 11 -HSD2 activity could not be demonstrated.”
BackgroundSelf-citationSoro, A., Ingram, M. C., Tonolo, G., Glorioso, N., & Fraser, R. (1995) · Hypertension · doi:10.1161/01.hyp.25.1.67 · Cited by 164
Monder, C., Shackleton, C. H. L., Bradlow, H. L., New, M. I., Stoner, E., Iohan, F., & Lakshmi, V. M. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-3-550 · Cited by 145 · cited 2×
“THF ratio, suggesting an additional defect in 5 -reductase activity (12, 13).”
BackgroundMethodMolecular Basis of Human Salt Sensitivity: The Role of the 11β-Hydroxysteroid Dehydrogenase Type 2*
Lovati, E., Ferrari, P., Dick, B., Jostarndt, K., Frey, B. M., Frey, F. J., Schorr, U., & Sharma, A. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6098 · Cited by 142 · cited 1×
“Studies have evaluated a microsatellite within intron 1 of the HSD11B2 gene and documented association with salt sensitivity in both normal subjects and patients with hypertension (53, 54).”
BackgroundWilson, R. C. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.11.3145 · Cited by 140
A genetic defect resulting in mild low-renin hypertension
Wilson, R. C., Dave-Sharma, S., Wei, J.-Q., Obeyesekere, V. R., Li, K., Ferrari, P., Krozowski, Z. S., Shackleton, C. H. L., Bradlow, L., Wiens, T., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.10200 · Cited by 140
Ulick, S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.5.963 · Cited by 135
CA-Repeat Polymorphism in Intron 1 of HSD11B2: Effects on Gene Expression and Salt Sensitivity
Agarwal, A. K., Giacchetti, G., Lavery, G., Nikkila, H., Palermo, M., Ricketts, M., McTernan, C., Bianchi, G., Manunta, P., Strazzullo, P., et al. (2000) · Hypertension · doi:10.1161/01.hyp.36.2.187 · Cited by 129 · cited 2×
“Salt-sensitive individuals appear to have impaired 11 -HSD2 activity as measured by increased urinary cortisol/cortisone ratios (53).”
BackgroundSelf-citationType 2 11 beta-hydroxysteroid dehydrogenase in human fetal tissues
Stewart, P. M., Murry, B. A., & Mason, J. I. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.8200959 · Cited by 126
Self-citationWalker, B. R., Connacher, A. A., Webb, D. J., & Edwards, C. R. W. (1992) · Clinical Science · doi:10.1042/cs0830171 · Cited by 124 · cited 1×
“In vitro and in vivo studies indicate that 11 -HSDs regulate vascular tone at an autocrine level through the amplification of responses to vasoconstrictors (57).”
BackgroundSchoof, E., Girstl, M., Frobenius, W., Kirschbaum, M., Dörr, H. G., Rascher, W., & Dotsch, J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7311 · Cited by 124
Diederich, S., Großmann, C., Hanke, B., Quinkler, M. O., Herrmann, M., Bähr, V., & Oelkers, W. (2000) · European Journal of Endocrinology · doi:10.1530/eje.0.1420200 · Cited by 115
Self-citationIntracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension
Gómez-Sánchez, E. P., Fort, C., & Gómez-Sánchez, C. E. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.3.e482 · Cited by 113 · cited 1×
“In rats with hypertension induced by systemic carbenoxolone or high-sodium diet, the blood pressure was lowered by icv infusions of a MR antagonist (61).”
BackgroundAgarwal, A. K., Rogerson, F. M., Mune, T., & White, P. C. (1995) · Genomics · doi:10.1006/geno.1995.1231 · Cited by 112
THE KIDNEY IS THE MAJOR SITE OF CORTISONE PRODUCTION IN MAN
WHITWORTH, J. A., STEWART, P. M., BURT, D., ATHERDEN, S. M., & EDWARDS, C. R. W. (1989) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1989.tb01259.x · Cited by 110 · cited 1×
“Plasma cortisone concentrations are reduced in patients with renal disease (39, 40) with an inverse correlation between cortisone values and plasma creatinine.”
BackgroundSelf-citationShackleton, C. H. L., RODRIGUEZ, J., Arteaga, E., LOPEZ, J. M., & Winter, J. S. D. (1985) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1985.tb00160.x · Cited by 104 · cited 2×
“THF ratio, suggesting an additional defect in 5 -reductase activity (12, 13).”
BackgroundMethodKawai, S., Ichikawa, Y., & Homma, M. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-5-848 · Cited by 90
Pathogenesis of the Type 2 Variant of the Syndrome of Apparent Mineralocorticoid Excess*
Ulick, S., Tedde, R., & Mantero, F. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-70-1-200 · Cited by 88
Watson, B., Bergman, S. M., Myracle, A., Callen, D. F., Acton, R. T., & Warnock, D. G. (1996) · Hypertension · doi:10.1161/01.hyp.28.3.478 · Cited by 83 · cited 1×
“One study has reported an association between a microsatellite marker close to the HSD11B2 gene and hypertension in African-Americans with hypertensive endstage renal disease (50).”
BackgroundHadoke, P. W. F., Christy, C., Kotelevtsev, Y. V., Williams, B. C., Kenyon, C. J., Seckl, J. R., Mullins, J. J., & Walker, B. R. (2001) · Circulation · doi:10.1161/hc4801.100077 · Cited by 82 · cited 1×
“11 -HSD2 knockout mice demonstrate increased arterial reactivity to norepinephrine and a decreased endothelium-derived nitric oxide synthase activity (60).”
BackgroundApparent mineralocorticoid excess: Type I and type II
Mantero, F., Palermo, M., Petrelli, M. D., Tedde, R., Stewart, P. M., & Shackleton, C. H. L. (1996) · Steroids · doi:10.1016/0039-128x(96)00012-8 · Cited by 77
Self-citationApparent mineralocorticoid excess
Wilson, R. C., Nimkarn, S., & New, M. I. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00356-8 · Cited by 75
Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state
Li, A., Li, K. X. Z., Marui, S., Krozowski, Z. S., Batista, M. C., Whorwood, C. B., Arnhold, I. J. P., Shackleton, C. H. L., Mendonca, B. B., & Stewart, P. M. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715120-00005 · Cited by 75 · cited 1×
“Type II AME is also explained on the basis of mutations in the HSD11B2 gene (26, 27).”
BackgroundSelf-citationReduced activity of 11β-hydroxysteroid dehydrogenase in patients with cholestasis
Quattropani, C., Vogt, B., Odermatt, A., Dick, B., Frey, B. M., & Frey, F. J. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12745 · Cited by 69 · cited 1×
“Patients with both alcoholic and nonalcoholic chronic liver disease or bile duct obstruction have an increase in their urinary THF allo-THF/THE ratio, suggesting a reduction in renal 11 -HSD2 activity (43, 44).”
BackgroundNunez, B. S., Rogerson, F. M., Mune, T., Igarashi, Y., Nakagawa, Y., Phillipov, G., Moudgil, A., Travis, L. B., Palermo, M., Shackleton, C., et al. (1999) · Hypertension · doi:10.1161/01.hyp.34.4.638 · Cited by 68
Brand, E., Kato, N., Chatelain, N., Krozowski, Z. S., Jeunemaître, X., Corvol, P. L., Plouin, P., Cambien, F., Pascoe, L., & Soubrier, F. (1998) · Journal of Hypertension · doi:10.1097/00004872-199816110-00009 · Cited by 66
Kitanaka, S., Tanae, A., & Hibi, I. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.677500.x · Cited by 64 · cited 1×
“The poor growth rate seen in many children with AME is possibly due to glucocorticoid excess in utero consequent on absent or impaired 11 -HSD2 activity (66, 67).”
BackgroundDetection of glycyrrhetinic acid-like factors (GALFs) in human urine.
Morris, D. J., Semafuko, W. E. B., Latif, S., Vogel, B., Grimes, C. A., & Sheff, M. F. (1992) · Hypertension · doi:10.1161/01.hyp.20.3.356 · Cited by 61 · cited 1×
“These so called glycyrrhetinic-acid-like factors are elevated during pregnancy, especially during the second and third trimester (33), suggesting that they might be progesterone metabolites.”
BackgroundQuinkler, M. O., Johanssen, S., Großmann, C., Bähr, V., Müller, M., Oelkers, W., & Diederich, S. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6163 · Cited by 60 · cited 1×
“This may be due to inhibition of 11 HSD2 by some unknown factor or by progesterone and its metabolites (70).”
BackgroundSelf-citationKageyama, Y., Suzuki, H., & Saruta, T. (1992) · Journal of Endocrinology · doi:10.1677/joe.0.1350147 · Cited by 54 · cited 1×
“Licorice administration to normal volunteers results in a mineralocorticoid excess state, an increase in the urinary THF allo-THF/THE ratio, an increase in plasma cortisol half-life, and a decrease in circulating cortisone values, indicative of inhibition of 11 HSD2 in vivo (30, 31).”
BackgroundStewart, P. M., Burra, P., Shackleton, C. H. L., Sheppard, M. C., & Elias, E. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.3.8445034 · Cited by 54
Self-citationCure of Apparent Mineralocorticoid Excess by Kidney Transplantation
Palermo, M., Cossu, M., & Shackleton, C. H. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812103392414 · Cited by 53
A New Polymorphic Restriction Site in the Human 11β-Hydroxysteroid Dehydrogenase Type 2 Gene
Smolenicka, Z., Bach, E., Schaer, A., Liechti‐Gallati, S., Frey, B. M., Frey, F. J., & Ferrari, P. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4933 · Cited by 50 · cited 1×
“In terms of hypertension per se, however, linkage and/or association studies have been negative (51, 52).”
BackgroundStauffer, A. T., Rochat, M. K., Dick, B., Frey, F. J., & Odermatt, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201556200 · Cited by 47 · cited 1×
“This could be explained by the inhibitory action on 11 -HSD2 of bile acids, notably chenodeoxycholic acid and deoxycholic acid (45, 46).”
BackgroundPlasma Cortisone Concentration as Measured by Radioimmunoassay
SRIVASTAVA, L. S., WERK, E. E., THRASHER, K., SHOLITON, L. J., KOZERA, R., NOLTEN, W., & KNOWLES, H. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-36-5-937 · Cited by 47 · cited 1×
“Plasma cortisone concentrations are reduced in patients with renal disease (39, 40) with an inverse correlation between cortisone values and plasma creatinine.”
BackgroundKitanaka, S., Katsumata, N., Tanae, A., Hibi, I., Takeyama, K., Fuse, H., Kato, S., & Tanaka, T. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4455 · Cited by 45 · cited 1×
“Up to nine patients are compound heterozygotes, with each allele coding for an enzyme devoid of activity (24, 25).”
BackgroundSouness, G. W., Brem, A. S., & Morris, D. J. (2002) · Steroids · doi:10.1016/s0039-128x(01)00148-9 · Cited by 40
Human kidney 11β-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin?
Diederich, S., Quinkler, M., Miller, K., Heilmann, P., Schöneshöfer, M., & Oelkers, W. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1340301 · Cited by 37
Self-citationAPPARENT MINERALOCORTICOID EXCESS AND DEFICIENT 11β‐OXIDATION OF CORTISOL IN A YOUNG FEMALE
HARINCK, H. I. J., VAN BRUMMELEN, P., VAN SETERS, A. P., & MOOLENAAR, A. J. (1984) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1984.tb01388.x · Cited by 36
11β-Hydroxysteroid dehydrogenase in human vascular cells
Hatakeyama, H., Inaba, S., Takeda, R., & Miyamori, I. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00974.x · Cited by 33
VASCULAR LOCALIZATION OF THE 11β‐HYDROXYSTEROID DEHYDROGENASE TYPE II ENZYME
Smith, R. E., Little, P. J., Maguire, J. A., Stein‐Oakley, A. N., & Krozowski, Z. S. (1996) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1996.tb02776.x · Cited by 31 · cited 1×
“In addition to enhanced renal sodium retention, the modulation of active glucocorticoid concentration by 11 -HSD in vascular smooth muscle cells could be an additional factor underlying hypertension (56).”
Renal 11 beta-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril
Riddle, M., & McDaniel, P. A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.4.8157707 · Cited by 30 · cited 1×
“ACE inhibitors are known to increase renal 11 -HSD2 activity, and this, in part, may explain their natriuretic effect (42).”
BackgroundEndogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertension
Walker, B. R., Aggarwal, I., Stewart, P. M., Padfield, P. L., & Edwards, C. R. W. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.2.7852515 · Cited by 27
Self-citationWhite, P. C., Agarwal, A. K., Li, A., Nikkilä, H., Pratt, J. H., Caulfield, M. J., Clark, A., McTernan, C. L., & Stewart, P. M. (2001) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2001.01314.x · Cited by 26
Self-citationRole of central mineralocorticoid receptors in cardiovascular disease
Gómez-Sánchez, C. E., & Gómez-Sánchez, E. P. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0049-z · Cited by 19 · cited 1×
“These studies provide evidence of the importance of the central nervous system and its effects on salt appetite, baroreceptor function, and autonomic nerve regulation in the pathogenesis of hypertension produced by systemic mineralocorticoid excess (62).”
BackgroundHeilmann, P., Buchheim, E., Wacker, J., & Ziegler, R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8049 · Cited by 16 · cited 1×
“Reduced 11 -HSD2 expression has been reported in placentas of women with preeclampsia and pregnancy-induced hypertension (71, 72).”
Background11 beta-Hydroxysteroid dehydrogenase: pathophysiology.
Vogt, B., Bm, F., & Frey, F. J. (1999) · PubMed · Cited by 5
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Jaffe, I. Z., & Mendelsohn, M. E. (2005) · Circulation Research · doi:10.1161/01.res.0000159937.05502.d1 · Cited by 358
Caprio, M., Newfell, B. G., la Sala, A., Baur, W., Fabbri, A., Rosano, G., Mendelsohn, M. E., & Jaffe, I. Z. (2008) · Circulation Research · doi:10.1161/circresaha.108.174235 · Cited by 285
Nagata, K., Obata, K., Xu, J., Ichihara, S., Noda, A., Kimata, H., Kato, T., Izawa, H., Murohara, T., & Yokota, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000203772.78696.67 · Cited by 223
Salivary cortisone is a potential biomarker for serum free cortisol
Perogamvros, I., Keevil, B. G., Ray, D. W., & Trainer, P. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1215 · Cited by 222
“On the other hand, the combined quantification of these compounds may be used as a tool in the study of 11 -HSD2 activity, in a similar way that the ratio of urinary free cortisol to urinary free cortisone is used for the same purpose (30).”
BackgroundMethod
Metadata
- Authors
- Quinkler, M., & Stewart, P. M.
- Affiliations
- Queen Elizabeth Hospital Birmingham (GB)
- Corresponding author
- Stewart, Paul M.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06
- Volume
- 88
- Issue
- 6
- Pages
- 2384-2392
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2087582614
- Semantic Scholar
- 776fe230acf2defba35d92035bb5d6c7ce782d64
- Cited by
- 286
- References
- 70
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 8 · 2021: 10 · 2020: 15 · 2019: 6 · 2018: 11 · 2017: 11 · 2016: 10 · 2015: 13 · 2014: 12 · 2013: 13 · 2012: 14
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- hypertension, 11β-hydroxysteroid dehydrogenase type 2, mineralocorticoid receptor, apparent mineralocorticoid excess, licorice, carbenoxolone, preeclampsia, sodium retention, Cushing's syndrome, ectopic ACTH syndrome, salt sensitivity, Barker hypothesis, fetal growth restriction, sodium homeostasis, substrate saturation
- MeSH terms
- Cortisone, Humans, Hydrocortisone, Hydroxysteroid Dehydrogenases, Hypertension, Mineralocorticoids, 11-beta-Hydroxysteroid Dehydrogenase Type 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.